The long haul COVID-19 arterial thrombosis

Borrelli, Maria; Buora, Adelaide; Frigatti, Paolo

doi:10.1016/j.thromres.2022.07.008

Cited by 4 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A dysregulation of the adaptive immune system, particularly involving CD4+ and CD8+ T cell exhaustion or upregulation, could cause long COVID symptoms, 91 , 92 and increased risk of blood clots. 93 Evidence of this was found among 25 convalescent COVID-19 survivors during longitudinal follow-up. 94 Their CD8+ T lymphocytes returned to normal 4 months after symptom onset while CD4+ lymphocytes remained low in half of the patients.…”

Section: Cardiac Dysautonomia and Arrhythmiasmentioning

confidence: 95%

Beyond Acute COVID-19: A Review of Long-term Cardiovascular Outcomes

Parhizgar¹,

Yazdankhah²,

Rzepka³

et al. 2023

Canadian Journal of Cardiology

View full text Add to dashboard Cite

Section: Cardiac Dysautonomia and Arrhythmiasmentioning

confidence: 95%

Beyond Acute COVID-19: A Review of Long-term Cardiovascular Outcomes

Parhizgar¹,

Yazdankhah²,

Rzepka³

et al. 2023

Canadian Journal of Cardiology

View full text Add to dashboard Cite

The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management

Becker,

Tantry,

Khan

et al. 2024

J Thromb Thrombolysis

View full text Add to dashboard Cite

A heightened risk for thrombosis is a hallmark of COVID-19. Expansive clinical experience and medical literature have characterized small (micro) and large (macro) vessel involvement of the venous and arterial circulatory systems. Most events occur in patients with serious or critical illness in the hyperacute (first 1–2 weeks) or acute phases (2–4 weeks) of SARS-CoV-2 infection. However, thrombosis involving the venous, arterial, and microcirculatory systems has been reported in the subacute (4–8 weeks), convalescent (> 8–12 weeks) and chronic phases (> 12 weeks) among patients with mild-to-moderate illness. The purpose of the current focused review is to highlight the distinguishing clinical features, pathological components, and potential mechanisms of venous, arterial, and microvascular thrombosis in patients with COVID-19. The overarching objective is to better understand the proclivity for thrombosis, laying a solid foundation for screening and surveillance modalities, preventive strategies, and optimal patient management. Graphical abstract Thrombosis involving the arterial, venous, and microvascular circulatory systems is a hallmark of COVID-19 contributing to organ injury, morbidity, and mortality. The COVID-19 thrombus has unique and distinct characteristics. Among them are a highly inflammatory signature on a foundation of endothelial cell inflammation and neutrophil extracellular traps (NETs). While the SARS-CoV-2 virus and resulting host immunoinflammatory response to this pathogen provide an underpinning for vascular events, the virus spike protein is necessary and likely sufficient for acute, subacute, and potentially in a latent form harbored in adipocytes, vascular endothelial cells, and circulating monocytes potentially contributing to post-infectious atherothrombotic phenotypes.

show abstract

Mechanisms of long COVID: An updated review

Liu,

Gu,

et al. 2023

Chinese Medical Journal Pulmonary and Critical Care Medicine

View full text Add to dashboard Cite

The long haul COVID-19 arterial thrombosis

Cited by 4 publications

References 11 publications

Beyond Acute COVID-19: A Review of Long-term Cardiovascular Outcomes

Beyond Acute COVID-19: A Review of Long-term Cardiovascular Outcomes

The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management

Mechanisms of long COVID: An updated review

Contact Info

Product

Resources

About